SPECT- and PET-Based Patient-Tailored Treatment in Neuroendocrine Tumors: A Comprehensive Multidisciplinary Team Approach

Abstract The overexpression of somatostatin receptors on the tumor cell surface of neuroendocrine tumors (NETs) detected by multimodal functional imaging modalities such as SPECT and PET tracers constitutes a therapeutic option using targeting radiolabeled compounds. We will introduce the theranostic concept in general, explain in more detail its development in NETs, and discuss available SPECT and PET tracers regarding their potential for diagnostic imaging, visualization of target expression, and treatment tailoring. Moreover, we will discuss the currently available peptide receptor radionuclide therapy principles and compare them to previously published studies. Finally, we will discuss which new concepts will most likely influence the theranostic treatment approach in NETs in the future.

[1]  I. Kayani,et al.  The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy , 2010, Journal of Nuclear Medicine.

[2]  B. Cruickshank,et al.  The Carcinoid Tumour , 1949, Edinburgh medical journal.

[3]  L. Schwartz,et al.  Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial 177Lu/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy. , 2013, Experimental oncology.

[4]  I. Modlin,et al.  Current status of gastrointestinal carcinoids. , 2005, Gastroenterology.

[5]  A. Runz,et al.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  M. Lassmann,et al.  Radiation Dosimetry Aspects of (177)Lu. , 2015, Current radiopharmaceuticals.

[7]  B. Bernard,et al.  111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  A. Dhillon,et al.  Multimodality treatment for gastric carcinoid tumor with liver metastases , 1998, American Journal of Gastroenterology.

[9]  L. Kvols,et al.  Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? , 2008, Cancer control : journal of the Moffitt Cancer Center.

[10]  R. Baum,et al.  Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Michael V Knopp,et al.  A comprehensive overview of radioguided surgery using gamma detection probe technology , 2009, World journal of surgical oncology.

[12]  H. Biersack,et al.  Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  S. Schulz,et al.  Intracellular trafficking of somatostatin receptors , 2008, Molecular and Cellular Endocrinology.

[14]  J. Mortensen,et al.  Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET , 2010, Journal of Nuclear Medicine.

[15]  Giovanni Paganelli,et al.  Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  S. Ricci,et al.  Everolimus in combination with octreotide long‐acting repeatable in a first‐line setting for patients with neuroendocrine tumors: An ITMO group study , 2014, Cancer.

[17]  A. Grossman,et al.  The diagnosis and medical management of advanced neuroendocrine tumors. , 2004, Endocrine reviews.

[18]  G. Glatting,et al.  Treatment planning in molecular radiotherapy. , 2013, Zeitschrift fur medizinische Physik.

[19]  H. Biersack,et al.  Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate , 2013, The Journal of Nuclear Medicine.

[20]  A. Hackshaw,et al.  Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours , 2010, British Journal of Cancer.

[21]  C. Streffer.  Genomic Instability Induced by Ionizing Radiation , 2022 .

[22]  R. Jensen,et al.  Gastroenteropancreatic neuroendocrine tumours. , 2008, The Lancet. Oncology.

[23]  E. Krenning,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs , 2009, Neuroendocrinology.

[24]  B. Sirohi,et al.  Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Valkema,et al.  Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. , 2002, Seminars in nuclear medicine.

[27]  B. Göke,et al.  Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin , 2011, Gut.

[28]  Raffaella Barone,et al.  Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  R. Jian,et al.  The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors , 2000, American Journal of Gastroenterology.

[30]  S. Schulz,et al.  Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  J. Turner,et al.  Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. , 2012, Cancer biotherapy & radiopharmaceuticals.

[32]  A. Buck,et al.  [¹²³I]Iodometomidate imaging in adrenocortical carcinoma. , 2013, The Journal of clinical endocrinology and metabolism.

[33]  T. Visser,et al.  Pre‐clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor‐targeted scintigraphy and radionuclide therapy , 1998, International journal of cancer.

[34]  E. Nitzsche,et al.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  S. M. Seidlin,et al.  Radioactive iodine therapy: Effect on functioning metastases ofadenocarcinoma of the thyroid , 1990, CA: a cancer journal for clinicians.

[36]  Osamu Okazaki,et al.  Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis , 2014, EJNMMI Research.

[37]  R. Baum,et al.  Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  C. Nutting,et al.  Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients , 2008, American journal of clinical oncology.

[39]  E. Krenning,et al.  Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  A. Buck,et al.  [123I]Iodometomidate imaging in adrenocortical carcinoma , 2013 .

[41]  L. Królicki,et al.  Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[42]  S. Lamberts,et al.  Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. , 2003, Endocrine-related cancer.

[43]  C. Schade-Brittinger,et al.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  M. Lubberink,et al.  Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177Lu-DOTA-Octreotate Treatment , 2013, The Journal of Nuclear Medicine.

[45]  E P Krenning,et al.  Neuroendocrine tumors and somatostatin: imaging techniques. , 2005, Journal of endocrinological investigation.

[46]  J. Turner,et al.  Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[47]  D. Niethammer,et al.  SCINTIGRAPHIC IMAGING OF NEUROBLASTOMA WITH [131I]IODOBENZYLGUANIDINE , 1984, The Lancet.

[48]  E. Krenning,et al.  Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  Eva Forssell-Aronsson,et al.  Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro. , 2006, Nuclear medicine and biology.

[50]  G. Kaltsas,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations , 2008, Neuroendocrinology.

[51]  M. Lassmann,et al.  EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[52]  H. Ishitsuka,et al.  X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  E. P. Krenning,et al.  Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients , 1993, European Journal of Nuclear Medicine.

[54]  W. Weber,et al.  First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible , 2011, The Journal of Nuclear Medicine.

[55]  H. Biersack,et al.  Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[56]  F. Berthold,et al.  Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  L. Vlahos,et al.  Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[58]  J. Stockman,et al.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .

[59]  J. Reubi,et al.  Highly Efficient In Vivo Agonist-Induced Internalization of sst2 Receptors in Somatostatin Target Tissues , 2009, Journal of Nuclear Medicine.

[60]  P. Ell,et al.  Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors , 2013, The Journal of Nuclear Medicine.

[61]  Michael Lassmann,et al.  The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[62]  E. Krenning,et al.  [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study , 2012, EJNMMI Research.

[63]  E. P. Krenning,et al.  LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN , 1989, The Lancet.

[64]  A. Buck,et al.  Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy , 2014, EJNMMI Research.

[65]  F. Mottaghy,et al.  Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[66]  Matthias Briel,et al.  Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Charles Pecher.  Biological Investigations with Radioactive Calcium and Strontium.∗ , 1941 .

[68]  M. Stridsberg,et al.  Tumor Markers in Neuroendocrine Tumors , 2000, Digestion.

[69]  A. Sundin.  Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. , 2012, Best practice & research. Clinical gastroenterology.

[70]  L. Breimer,et al.  Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[71]  S. Schulz,et al.  New Pansomatostatin Ligands and Their Chelated Versions: Affinity Profile, Agonist Activity, Internalization, and Tumor Targeting , 2008, Clinical Cancer Research.

[72]  R. Parks,et al.  Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[73]  Eva Forssell-Aronsson,et al.  Intraoperative tumour detection using 111In-DTPA-D-Phe1-octreotide and a scintillation detector , 2001, European Journal of Nuclear Medicine.